Hims & Hers Health (NYSE:HIMS) vs. biote (NASDAQ:BTMD) Head-To-Head Contrast

biote (NASDAQ:BTMD) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Volatility & Risk

biote has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.

Profitability

This table compares biote and Hims & Hers Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

Institutional & Insider Ownership

21.7% of biote shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 32.4% of biote shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for biote and Hims & Hers Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1	1	1	1	2.50
Hims & Hers Health	1	12	3	0	2.12

biote presently has a consensus target price of $2.50, suggesting a potential upside of 117.39%. Hims & Hers Health has a consensus target price of $32.43, suggesting a potential upside of 5.08%. Given biote’s stronger consensus rating and higher possible upside, equities analysts clearly believe biote is more favorable than Hims & Hers Health.

Valuation & Earnings

This table compares biote and Hims & Hers Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$183.53 million	0.23	$27.05 million	$0.11	10.45
Hims & Hers Health	$2.35 billion	3.07	$128.37 million	($0.63)	-48.99

Hims & Hers Health has higher revenue and earnings than biote. Hims & Hers Health is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Summary

biote beats Hims & Hers Health on 8 of the 15 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.